Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary aldosteronism - treatment options.

William F Young1

  • 1Divisions of Endocrinology, Metabolism, Nutrition and Internal Medicine, Mayo Medical School, Mayo Clinic and Mayo Foundation, 200 First Street S.W., Rochester, MN 55905, USA. young.william@mayo.edu

Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society
|August 14, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety of biopsy in phaeochromocytoma and paraganglioma: an international, multicentre, retrospective cohort study.

The lancet. Diabetes & endocrinology·2026
Same author

Adrenal histologic and genetic characteristics of primary aldosteronism in late adulthood.

European journal of endocrinology·2026
Same author

Endocrine and metabolic determinants of cardiometabolic risk in mild autonomous cortisol secretion.

EBioMedicine·2026
Same author

Cardiometabolic Outcomes after Surgical Remission of Endogenous Hypercortisolism: A Prospective Cohort Study.

The Journal of clinical endocrinology and metabolism·2025
Same author

Duration of adrenal insufficiency after surgical treatment of endogenous hypercortisolism: a prospective cohort study.

European journal of endocrinology·2025
Same author

A comparison of bilateral internal jugular vein sampling with bilateral inferior petrosal sinus sampling at Mayo Clinic for the subtype evaluation of corticotropin-dependent cushing syndrome.

Pituitary·2025
Same journal

Dose optimization and safety of long-acting pegylated growth hormone in pubertal idiopathic short stature: A retrospective real-world group study.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society·2026
Same journal

Real world data on rhIGF-1 therapy in children with severe primary IGF-I deficiency - The European experience.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society·2026
Same journal

Effects of switching from somatropin to somapacitan on thyroid hormone levels in adult growth hormone deficiency: A pilot study.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society·2026
Same journal

Prognostic value of immediate and short-term postoperative biochemical markers for long-term remission in acromegaly: A single-center study.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society·2026
Same journal

Extended follow-up is crucial for diagnosing growth hormone deficiency after traumatic brain injury in children and adolescents.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society·2026
Same journal

Real world performance of once weekly somatrogon on naive patients with isolated growth hormone deficiency: Mind the weight gain.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society·2026
See all related articles

Primary aldosteronism diagnosis leads to surgery or medication. Eplerenone, a new selective drug, may be superior to spironolactone for treating hypertension caused by mineralocorticoid excess.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Hypertension Management

Background:

  • Primary aldosteronism is a leading cause of secondary hypertension.
  • The two main subtypes are unilateral aldosterone-producing adenoma (APA) and bilateral idiopathic hyperaldosteronism (IHA).
  • IHA is more common and typically managed with pharmacotherapy.

Purpose of the Study:

  • To compare the efficacy and safety of eplerenone versus spironolactone for treating mineralocorticoid-dependent hypertension.
  • To evaluate eplerenone as a potential superior alternative to spironolactone due to its selectivity.

Main Methods:

  • This study focuses on the pharmacological treatment of primary aldosteronism, specifically comparing aldosterone receptor antagonists.
  • The evaluation considers patient outcomes, hypertension management, and side effect profiles.

Related Experiment Videos

Main Results:

  • Spironolactone is the current drug of choice but has off-target effects like gynecomastia and menstrual irregularities.
  • Eplerenone is a newer, selective aldosterone receptor antagonist approved for hypertension treatment.
  • Eplerenone has a favorable side effect profile compared to spironolactone.

Conclusions:

  • Eplerenone presents a promising alternative for managing primary aldosteronism, particularly IHA.
  • Further clinical evidence is needed to confirm eplerenone's efficacy compared to spironolactone in mineralocorticoid-dependent hypertension.
  • Eplerenone's selectivity may offer improved patient tolerability and treatment adherence.